

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Collaboration Agreement Between Uniphase Corporation and the Perkin Elmer Corporation

Notice is hereby given that, on November 15, 1994, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Uniphase Corporation has filed written notifications of the formation of a collaboration on behalf of Uniphase Corporation and the Perkin Elmer Corporation simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are Uniphase Corporation, San Jose, CA; and the Perkin Elmer Corporation, Foster City, CA. The general area of planned activity is the development of blue laser for DNA diagnostics.

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 95-3914 Filed 2-15-95; 8:45 am]

BILLING CODE 4410-01-M

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated March 18, 1994, and published in the **Federal Register** on March 28, 1994, (59 FR 14426), and by Notice dated May 6, 1994, and published in the **Federal Register** on May 13, 1994, (59 FR 25126), Mallinckrodt, Specialty Chemical Company, Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Sched- ule
Tetrahydrocannabinols (7370)	I
Methylphenidate (1724)	II
Cocaine (9041)	II
Codeine (9050)	II
Diprenorphine (9058)	II
Etorphine Hydrochloride (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Diphenoxylate (9170)	II
Benzoylcegonine (9180)	II

Drug	Sched- ule
Hydrocodone (9193)	II
Levorphanol (9220)	II
Meperidine (9230)	II
Methadone (9250)	II
Methadone-intermediate (9254)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Thebaine (9333)	II
Opium extracts (9610)	II
Opium fluid extract (9620)	II
Opium tincture (9630)	II
Opium powdered (9639)	II
Opium granulated (9640)	II
Oxymorphone (9652)	II
Alfentanil (9737)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

A registered manufacturer did file a written request for a hearing with respect to Methylphenidate. Therefore, pursuant to Section 303 of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and Title 21, code of Federal Regulations, Section 1301.54(e), Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted with the exception of Methylphenidate.

Dated: February 6, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 95-3818 Filed 2-15-95; 8:45 am]

BILLING CODE 4410-09-M

NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES

Notice of Meeting

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Design Advisory Panel (Grants for Organizations Section) to the National Council on the Arts will be held on March 7-10, 1995. The panel will meet from 8:30 a.m. to 6:30 p.m. on March 7; from 8:30 a.m. to 7:30 p.m. on March 8; from 8:30 a.m. to 7:00 p.m. on March 9; and from 8:30 a.m. to 4:30 p.m. on March 10 in Room M-07, at the Nancy Hanks Center, 1100 Pennsylvania Avenue, N.W., Washington, D.C. 20506.

A portion of this meeting will be open to the public on March 10, from 2:30 p.m. to 4:30 p.m. for a policy discussion.

Remaining portions of this meeting from 8:30 a.m. to 6:30 p.m. on March 7; from 8:30 a.m. to 7:30 p.m. on March 8; from 8:30 a.m. to 7:00 p.m. on March 9; and from 8:30 a.m. to 2:30 p.m. on March 10 are for the purpose of panel review, discussion, evaluation, and recommendation on applications for financial assistance under the National Foundation on the Arts and the Humanities Act of 1965, as amended, including information given in confidence to the agency by grant applicants. In accordance with the determination of the Chairman of February 8, 1994, these sessions will be closed to the public pursuant to subsection (c) (4), (6) and (9)(B) of section 552b of Title 5, United States Code.

Any person may observe meetings, or portions thereof, of advisory panels which are open to the public, and may be permitted to participate in the panel's discussions at the discretion of the Panel chairman and with the approval of the full-time Federal employee in attendance.

If you need special accommodations due to a disability, please contact the Office of Special Constituencies, National Endowment for the Arts, 1100 Pennsylvania Avenue, N.W., Washington, D.C., 20506, 202/682-5532, TTY 202/682-5496, at least seven (7) days prior to the meeting.

Further information with reference to this meeting can be obtained from Ms. Yvonne M. Sabine, Committee Management Officer, National Endowment for the Arts, Washington, D.C., 20506, or call 202/682-5433.

Dated: February 13, 1995.

Yvonne M. Sabine,

Director, Office of Council and Panel Operations, National Endowment for the Arts.

[FR Doc. 95-3938 Filed 2-15-95; 8:45 am]

BILLING CODE 7537-01-M

Notice of Meeting

Pursuant to section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92-463), as amended, notice is hereby given that a meeting of the Folk and Traditional Arts Advisory Panel (National Heritage Fellowship Section) to the National Council on the Arts will be held on March 8-10, 1995. The panel will meet from 9:00 a.m. to 10:00 p.m. on March 8; from 9:00 a.m. to 6:30 p.m. on March 9; and from 9:00 a.m. to 4:00 p.m. on March 10 in Room 716, at the Nancy Hanks Center, 1100 Pennsylvania Avenue N.W., Washington, D.C. 20506.

This meeting is for the purpose of application evaluation, under the National Foundation on the Arts and